

Philippe Chavatte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2212911/publications.pdf>

Version: 2024-02-01

84
papers

3,003
citations

236612

25
h-index

168136

53
g-index

89
all docs

89
docs citations

89
times ranked

4525
citing authors

#	ARTICLE	IF	CITATIONS
1	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor- β . <i>Journal of Experimental Medicine</i> , 2005, 201, 1205-1215.	4.2	428
2	PPAR α as a new therapeutic target in inflammatory bowel diseases. <i>Gut</i> , 2006, 55, 1341-1349.	6.1	363
3	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8772-8777.	3.3	183
4	Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4027-4061.	2.9	160
5	Three-Dimensional Quantitative Structure-Activity Relationships of Cyclo-oxygenase-2 (COX-2) Inhibitors: A Comparative Molecular Field Analysis. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3223-3230.	2.9	105
6	Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and <i>N</i> -Acylethanolamine Acid Amidase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4-46.	2.9	89
7	Synthesis and Structure-Affinity-Activity Relationships of Novel Benzofuran Derivatives as MT2 Melatonin Receptor Selective Ligands. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 2788-2800.	2.9	88
8	2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database. <i>Journal of Chemical Information and Computer Sciences</i> , 2004, 44, 276-285.	2.8	81
9	Novel 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New CB2 Cannabinoid Receptors Agonists: A Synthesis, Pharmacological Properties and Molecular Modeling. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 70-79.	2.9	81
10	Novel Benzopyridothiadiazepines as Potential Active Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7363-7373.	2.9	76
11	Switching Invariant Natural Killer T (iNKT) Cell Response from Anticancerous to Anti-Inflammatory Effect: Molecular Bases. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5489-5508.	2.9	62
12	Design and Synthesis of Naphthalenic Dimers as Selective MT1 Melatonergic Ligands. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1127-1129.	2.9	61
13	Synthesis and Structure-Activity Relationships of (Aryloxy)quinazoline Ureas as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1189-1204.	2.9	55
14	Characterisation of novel defective thiopurine S-methyltransferase allelic variants. <i>Biochemical Pharmacology</i> , 2008, 76, 404-415.	2.0	53
15	Structural Insight into PPAR γ ; Ligands Binding. <i>Current Medicinal Chemistry</i> , 2009, 16, 1768-1789.	1.2	46
16	Investigations of new lead structures for the design of novel cyclooxygenase-2 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2002, 37, 461-468.	2.6	45
17	Preclinical Studies of a Specific PPAR β Modulator in the Control of Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1001-1011.	0.3	44
18	Pharmacophoric Search and 3D-QSAR Comparative Molecular Field Analysis Studies on Agonists of Melatonin Sheep Receptors. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4453-4465.	2.9	43

#	ARTICLE	IF	CITATIONS
19	New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3777-3786.	1.4	38
20	Docking Study of Ligands into the Colchicine Binding Site of Tubulin. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2004, 19, 541-547.	2.5	36
21	3-Carboxamido-5-aryl-isoxazoles as new CB ₂ agonists for the treatment of colitis. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5383-5394.	1.4	36
22	Toward the Discovery of a Novel Class of YAP/TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP/TEAD Protein-Protein Interface. <i>Cancers</i> , 2018, 10, 140.	1.7	36
23	Recent Advances in the Development of Selective CB ₂ Agonists as Promising Anti-Inflammatory Agents. <i>Current Medicinal Chemistry</i> , 2012, 19, 3457-3474.	1.2	33
24	4-Oxo-1,4-dihydropyridines as Selective CB ₂ Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7918-7931.	2.9	30
25	Synthesis and Radioligand Binding Studies of Bis-isoquinolinium Derivatives as Small Conductance Ca ²⁺ -Activated K ⁺ Channel Blockers. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5070-5075.	2.9	27
26	Therapeutical Potential of CB ₁ and CB ₂ Receptors in Immune-Related Diseases. <i>Current Molecular Pharmacology</i> , 2014, 6, 183-203.	0.7	27
27	Comparative Molecular Field Analysis of Selective Cyclooxygenase-2 (COX-2) Inhibitors. <i>QSAR and Combinatorial Science</i> , 2000, 19, 127-134.	1.4	25
28	Molecular modelling of phthalates / PPARs interactions. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2008, 23, 611-616.	2.5	25
29	2,6-Diphenylthiazolo[3,2-b][1,2,4]triazoles as telomeric G-quadruplex stabilizers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3434-3438.	1.0	25
30	Homology modeling of MT1 and MT2 receptors. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 1926-1944.	2.6	23
31	Conformational Restriction Leading to a Selective CB ₂ Cannabinoid Receptor Agonist Orally Active Against Colitis. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 198-203.	1.3	23
32	Importance of the second extracellular loop for melatonin MT ₁ receptor function and absence of melatonin binding in GPR50. <i>British Journal of Pharmacology</i> , 2018, 175, 3281-3297.	2.7	23
33	Potent and Selective Farnesyl Transferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6812-6820.	2.9	22
34	Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT ₁ melatonergic ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3426-3436.	1.4	21
35	4-Oxo-1,4-dihydropyridines as Selective CB ₂ Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8948-8952.	2.9	21
36	Design, Synthesis, and Pharmacological Evaluation of New Farnesyl Protein Transferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 533-536.	2.9	20

#	ARTICLE	IF	CITATIONS
37	Identification of a pharmacophore of SKCa channel blockers. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2005, 20, 517-523.	2.5	19
38	Virtual Screening of CB ₂ Receptor Agonists from Bayesian Network and High-Throughput Docking: Structural Insights into Agonist-Modulated GPCR Features. <i>Chemical Biology and Drug Design</i> , 2013, 81, 442-454.	1.5	19
39	Enantioseparation of pyroglutamide derivatives on polysaccharide based chiral stationary phases by high-performance liquid chromatography and supercritical fluid chromatography: A comparative study. <i>Journal of Chromatography A</i> , 2014, 1363, 257-269.	1.8	19
40	Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPAR ^β agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 7377-7391.	1.4	18
41	Microwave-mediated synthesis and manipulation of a 2-substituted-5-aminooxazole-4-carbonitrile library. <i>Tetrahedron Letters</i> , 2012, 53, 1656-1659.	0.7	18
42	Chlorinated and brominated bisphenol A derivatives: Synthesis, characterization and determination in water samples. <i>Chemosphere</i> , 2018, 213, 434-442.	4.2	18
43	Antioxydant activity of $\hat{2}$ -carboline derivatives in the LDL oxidation model. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2575-2585.	2.6	17
44	Synthesis and preliminary pharmacological results on new naphthalene derivatives as 5-HT ₄ receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2000, 35, 699-706.	2.6	16
45	Differences in Binding Sites of Two Melatonin Receptors Help to Explain Their Selectivity to Some Melatonin Analogs: A Molecular Modeling Study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2006, 24, 91-107.	2.0	16
46	Solid-phase synthesis and pharmacological evaluation of a library of peptidomimetics as potential farnesyltransferase inhibitors: an approach to new lead compounds. <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 745-755.	2.6	16
47	Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT ₃ . <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 4954-4962.	1.4	16
48	Potent Farnesyltransferase Inhibitors with 1,4-Diazepane Scaffolds as Novel Destabilizing Microtubule Agents in Hormone-Resistant Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1178-1190.	2.9	16
49	Development of novel oxazolo[5,4-d]pyrimidines as competitive CB ₂ neutral antagonists based on scaffold hopping. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 68-78.	2.6	16
50	Genetic polymorphism of CYP4A11 and CYP4A22 genes and in silico insights from comparative 3D modelling in a French population. <i>Gene</i> , 2011, 487, 10-20.	1.0	15
51	Bis-tetrahydroisoquinoline derivatives: AG525E1, a new step in the search for non-quaternary non-peptidic small conductance Ca ²⁺ -activated K ⁺ channel blockers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3440-3445.	1.0	14
52	Docking study: PPARs interaction with the selected alternative plasticizers to di(2-ethylhexyl) phthalate. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 31, 1-8.	2.5	14
53	Design, synthesis and biological evaluation of potent FAAH inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2701-2705.	1.0	14
54	Design, Synthesis and In Vitro Evaluation of Novel Derivatives as Serotonin N -Acetyltransferase Inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2002, 17, 409-414.	2.5	13

#	ARTICLE	IF	CITATIONS
55	Quantitative structure-activity relationships studies of antioxidant hexahydropyridoindoles and flavonoid derivatives. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2007, 22, 556-562.	2.5	12
56	Switching cannabinoid response from CB2 agonists to FAAH inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1322-1326.	1.0	12
57	Scaffold hopping strategy toward original pyrazolines as selective CB2 receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2012, 58, 396-404.	2.6	11
58	Critical Role of Tyrosine 277 in the Ligand-Binding and Transactivating Properties of Retinoic Acid Receptor β . <i>Biochemistry</i> , 2000, 39, 2183-2192.	1.2	10
59	Conformation of the tripeptide Cbz-Pro-Leu-Trp-OBzl(CF ₃) ₂ deduced from two-dimensional ¹ H-NMR and conformational energy calculations is related to its affinity for NK1-receptor. <i>Journal of Peptide Science</i> , 2001, 7, 323-330.	0.8	10
60	Design, Synthesis and In Vitro Evaluation of Novel Benzo[b]thiophene Derivatives as Serotonin N-acetyltransferase (AANAT) Inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2003, 18, 119-125.	2.5	10
61	Homology modelling of the serotonergic 5-HT _{2c} receptor. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2006, 21, 285-292.	2.5	10
62	Synthesis of 2,3 and 4,5-Dihydro-hydroxy-isoxazoles and Isoxazoles Under Different pH Conditions. <i>Letters in Organic Chemistry</i> , 2010, 7, 32-38.	0.2	10
63	Novel structural insights for drug design of selective 5-HT _{2C} inverse agonists from a ligand-biased receptor model. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 5086-5099.	2.6	8
64	Development and validation of a reversed-phase HPLC method for the quantification of paclitaxel in different PLGA nanocarriers. <i>Electrophoresis</i> , 2017, 38, 2536-2541.	1.3	8
65	Lipid-lowering properties of 6-benzoyl-2(3H)-benzothiazolone and structurally related compounds. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2005, 20, 525-532.	2.5	7
66	Exploring chiral separation of 3-carboxamido-5-aryl isoxazole derivatives by supercritical fluid chromatography on amylose and cellulose tris dimethyl- and chloromethyl phenylcarbamate polysaccharide based stationary phases. <i>Journal of Chromatography A</i> , 2016, 1467, 473-481.	1.8	7
67	Synthesis and biological evaluation of conformationally restricted derivatives of tryptophan as NK1/NK2 ligands. <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 221-233.	0.1	6
68	Relationships between Th1 or Th2 iNKT Cell Activity and Structures of CD1d-Antigen Complexes: Meta-analysis of CD1d-Glycolipids Dynamics Simulations. <i>PLoS Computational Biology</i> , 2014, 10, e1003902.	1.5	5
69	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. <i>PLoS ONE</i> , 2021, 16, e0257281.	1.1	5
70	GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1272-1274.	4.8	4
71	Title is missing!. <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 221-233.	0.1	3
72	Three-Dimensional Quantitative Structure-Activity Relationship of MT3 Melatonin Binding Site Ligands: A Comparative Molecular Field Analysis. <i>QSAR and Combinatorial Science</i> , 2007, 26, 820-827.	1.5	3

#	ARTICLE	IF	CITATIONS
73	Conformational analysis of tripeptide Ac-Lys-Pro-Val-NH ₂ , COOH-terminal sequence of alpha-MSH. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 949-953.	1.2	3
74	Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines. <i>European Journal of Medicinal Chemistry</i> , 2015, 106, 15-25.	2.6	3
75	Preclinical Evaluation of Intestinal Anti-Inflammatory/Analgesic Properties and Phase I Clinical Trial of a New PPAR Agonist Ged-0507-34-Levo. <i>Gastroenterology</i> , 2011, 140, S-515.	0.6	2
76	Conformational investigations of two diastereoisomers of the tripeptide N [?] -Z-N [?] -Bz-Lys-Ala-Sar-OBzl. 1. Molecular dynamics simulations using the AMBER and the SPASIBA force fields. , 1997, 2, 195-205.		1
77	A Computational View of COX-2 Inhibition. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2006, 6, 239-249.	0.9	1
78	740 Development of a New Optimized 5-ASA Molecule Ged-0507-34 with Intestinal Anti-Inflammatory and Analgesic Properties. <i>Gastroenterology</i> , 2008, 134, A-106-A-107.	0.6	1
79	Three-Dimensional Quantitative Structure-Activity Relationship of Arylalkylamine N-acetyltransferase (AANAT) Inhibitors: A Comparative Molecular Field Analysis. <i>QSAR and Combinatorial Science</i> , 2001, 20, 414-421.	1.4	1
80	Conformational investigations of two diastereoisomers of the tripeptide N [?] -Z-N [?] -Bz-Lys-Ala-Sar-OBzl. 2. Infrared and Raman studies and normal modes analysis. , 1997, 2, 206-214.		0
81	2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database.. <i>ChemInform</i> , 2004, 35, no.	0.1	0
82	NMR studies of interactions of new CB2 cannabinoid receptor ligands with cyclodextrins hosts. Correlation with micellar electrokinetic chromatography and reversed phase high performance liquid chromatography. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2014, 78, 265-274.	0.9	0
83	Homology Modeling of 5-HT _{2C} Receptors. , 2011, , 97-127.		0
84	Molecular Modeling of Human MT1 and MT2 Melatonin Receptors. , 2006, , 259-270.		0